Logo

American Heart Association

  31
  0


Final ID: MP1168

A Novel Cardioprotective Mechanism in Myocardial Reperfusion Injury: Dual Neutrophil Modulation and ROS/HOCl Scavenging by an Atypical Chemokine

Abstract Body (Do not enter title and authors here): Background: Myocardial ischemia-reperfusion (IR) injury exacerbates cardiomyocyte death following acute myocardial infarction. Macrophage migration inhibitory factor (MIF) is a redox-sensitive cytokine and atypical chemokine known to exert context-dependent cardioprotective effects. The mechanisms are incompletely understood. We hypothesized that recombinant MIF (moMIF), when administered at reperfusion, may mitigate myocardial injury by scavenging neutrophil-derived reactive oxygen species (ROS) / hypochlorous acid (HOCl), a major oxidative effector of reperfusion injury, despite MIF’s effect on neutrophil attraction and its promoting effect on neutrophil priming.
Methods: Human neutrophil chemotaxis was quantified using a 3D μ-Slide chamber following stimulation with MIF (40 nM), oxidized MIF (noxMIF, 40 nM) or HOCl (100 nM). Migration was quantified by forward migration index (FMI). In parallel, male C57BL/6N mice (n=18) underwent 60 min left anterior descending (LAD) coronary occlusion followed by 48 h of reperfusion. Mice received intravenous phosphate buffer (control), mouse MIF (moMIF), or noxMIF (10 μg) 5 min before reperfusion. Myocardial infarct size (IS) and area at risk (AAR) were determined by Evans blue/TTC staining. Data were analyzed by one-way ANOVA with Bonferroni post-hoc correction.
Results: MIF significantly enhanced neutrophil migration (FMI 0.16±0.05 vs. control 0.02±0.02, P=0.0257), while, similar to HOCl control, noxMIF lacked chemotactic activity (FMI 0.03±0.05, P>0.9999; FMI -0.06±0.09, P=0.2090). In vivo, moMIF markedly reduced IS/AAR (39.23% ± 9.5%) compared to control (65.44% ± 14.03%, P=0.041). noxMIF did not confer protection (55.48% ± 7.6%, P=0.620 vs. control; P=0.056 vs. moMIF).
Conclusions: These findings identify moMIF as a dual-function cardioprotective agent when administered at reperfusion: it protects cardiomyocytes from IR damage, but also recruits neutrophils and enhances their HOCl production capacity. Our current data comparing the capacities of MIF vs noxMIF on neutrophil migration and cardiac IR damage in vivo, collectively identify noxMIF formation as a ROS/HOCl scavenging mechanism that also serves to limit the inflammatory recruitment response. Targeting MIF-ROS/HOCl interactions may represent a novel translational strategy to attenuate myocardial reperfusion injury.
  • Zwissler, Leon  ( Ludwig-Maximilians-University (LMU) , Munich , Germany )
  • Bernhagen, Juergen  ( Ludwig-Maximilians-University (LMU) , Munich , Germany )
  • Cabrera-fuentes, Hector Alejandro  ( Tecnologico Nacional de Mexico , Oaxaca , Oaxaca , Mexico )
  • Hernandez Resendiz, Sauri  ( Duke-NUS Medical School , Singapore , Singapore )
  • Yap, En Ping  ( Duke-NUS Medical School , Singapore , Singapore )
  • Schindler, Lisa  ( Ludwig-Maximilians-University (LMU) , Munich , Germany )
  • Zhang, Zhishen  ( Ludwig-Maximilians-University (LMU) , Munich , Germany )
  • Dickerhof, Nina  ( University of Otago , Christchurch , New Zealand )
  • Hampton, Mark  ( University of Otago , Christchurch , New Zealand )
  • Liehn, Elisa  ( National Heart Centre Singapore , Singapore , Singapore )
  • Hausenloy, Derek  ( Duke-NUS Medical School , Singapore , Singapore )
  • Author Disclosures:
    Leon Zwissler: No Answer | Juergen Bernhagen: No Answer | Hector Alejandro Cabrera-Fuentes: DO NOT have relevant financial relationships | Sauri Hernandez Resendiz: No Answer | En Ping Yap: No Answer | Lisa Schindler: No Answer | Zhishen Zhang: DO NOT have relevant financial relationships | Nina Dickerhof: No Answer | Mark Hampton: DO NOT have relevant financial relationships | Elisa A. Liehn: DO NOT have relevant financial relationships | Derek Hausenloy: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Redefining Cardioprotection: Molecular and Cellular Insights into Ischemic Heart Injury

Saturday, 11/08/2025 , 10:45AM - 11:55AM

Moderated Digital Poster Session

More abstracts on this topic:
A First-in-Class Humanized Antibody Fragment Targeting Platelet Glycoprotein Ibα: A Comprehensive Preclinical Study of CA1001 for the Treatment of Acute Ischemic Stroke

Xu Xiaohong, Preeti Preeti, Yu Ruoying, Shaykhalishahi Hamed, Zhang Cheng, Shen Chuanbin, Li Bei, Tang Naping, Chang Yan, Xiang Qian, Cui Yimin, Lei Xi, Ni Heyu, Zhu Guangheng, Liu Zhenze, Hu Xudong, Slavkovic Sladjana, Neves Miguel, Ma Wenjing, Xie Huifang

A Rationally Designed Cardioprotective Nanoparticle to Treat Chemotherapy-Induced Cardiotoxicity

Khatun Zehedina, Blanton Robert, Baleja James, Yang Vicky, Yuan Hushan, Chen Howard, Kung Andrew, Boukhalfa Asma, Thompson Anna-lee, Weng Sydney, Wei Lan, Meng Lin, Martin Gregory, Mekkaoui Choukri

You have to be authorized to contact abstract author. Please, Login
Not Available